المؤلفون: Tan, TM, Salem, V, Troke, RC, Alsafi, A, Field, BCT, De Silva, A, Misra, S, Baynes, KCR, Donaldson, M, Minnion, J, Ghatei, MA, Godsland, IF, Bloom, SR

المساهمون: Medical Research Council (MRC)

المصدر: E2324 ; E2317

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, BARIATRIC SURGERY, NEUROPEPTIDE-Y, FOOD-INTAKE, GASTRIC BYPASS, CELL FUNCTION, PYY3-36, SENSITIVITY, MORTALITY, APPETITE, RELEASE, Adult, Blood Glucose, Female, Glucagon-Like Peptide 1, Glucose, Glucose Tolerance Test, Homeostasis, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Obesity, Overweight, Peptide Fragments, Peptide YY, Young Adult

الوصف: Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.

العلاقة: Journal of Clinical Endocrinology and Metabolism; http://hdl.handle.net/10044/1/18802Test; G0701371; MR/J010936/1; G7811974; MR/K02115X/1; MR/J010731/1; G0802390; G1000474

الإتاحة: https://doi.org/10.1210/jc.2014-2143Test
http://hdl.handle.net/10044/1/18802Test

المؤلفون: Tan, TM, Field, BCT, McCullough, KA, Troke, RC, Chambers, ES, Salem, V, Maffe, JG, Baynes, KCR, De Silva, A, Viardot, A, Alsafi, A, Frost, GS, Ghatei, MA, Bloom, SR

المصدر: 1138 ; 1131

العلاقة: DIABETES; http://hdl.handle.net/10044/1/19662Test; http://dx.doi.org/10.2337/db12-0797Test

الإتاحة: https://doi.org/10.2337/db12-0797Test
http://hdl.handle.net/10044/1/19662Test